Literature DB >> 12732214

Sodium orthovanadate potentiates EGCG-induced apoptosis that is dependent on the ERK pathway.

Yun-Jung Choi1, Sung-Yup Lim, Ju-Hyung Woo, Young-Ho Kim, Young Kyu Kwon, Seong-Il Suh, Sung-Hee Lee, Wha-Youl Choi, Jong-Guk Kim, In-Seon Lee, Jong-Wook Park, Taeg-Kyu Kwon.   

Abstract

Epigallocatechin-3-gallate (EGCG) is a potent chemopreventive agent in many test systems and has been shown to inhibit tumor promotion and induce apoptosis. In the present study, we determined the effect of vanadate, a potent inhibitor of tyrosine phosphatase, on EGCG-induced apoptosis. Investigation of the mechanism of EGCG or vanadate-induced apoptosis revealed induction of caspase 3 activity and cleavage of phospholipase-gamma1 (PLC-gamma1). Furthermore, vanadate potentiated EGCG-induced apoptosis by mitogen-activated protein kinase (MAPK) signaling pathway. Treatment with EGCG plus vanadate for 24h produced morphological features of apoptosis and DNA fragmentation in U937 cells. This was associated with cytochrome c release, caspase 3 activation, and PLC-gamma1 degradation. EGCG plus vanadate activates multiple signal transduction pathways involved in coordinating cellular responses to stress. We demonstrate a requirement for extracellular signal-regulated protein kinase (ERK), a member of the mitogen-activated protein kinase family in EGCG plus vanadate-induced apoptosis in U937 cells. Elevated ERK activity that contributed to apoptosis by EGCG plus vanadate was supported by PD98059 and U0126, chemical inhibitor of MEK/ERK signaling pathway, prevented apoptosis. Taken together, our finding suggests that ERK activation plays an active role in mediating EGCG plus vanadate-induced apoptosis of U937 cells and functions upstream of caspase activation to initiate the apoptotic signal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732214     DOI: 10.1016/s0006-291x(03)00719-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Mechanisms involved in ceramide-induced cell cycle arrest in human hepatocarcinoma cells.

Authors:  Jing Wang; Xiao-Wen Lv; Jie-Ping Shi; Xiao-Song Hu
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

2.  Translocation of ethanolamine phosphoglyceride is required for initiation of apoptotic death in OLN-93 oligodendroglial cells.

Authors:  Annette Brand; Ephraim Yavin
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

3.  Epigallocatechin-3-gallate induces apoptosis, inhibits proliferation and decreases invasion of glioma cell.

Authors:  Hong Li; Zhe Li; Ya-Ming Xu; Yue Wu; Kang-Kang Yu; Can Zhang; Yong-Hua Ji; Gang Ding; Fu-Xue Chen
Journal:  Neurosci Bull       Date:  2013-12-13       Impact factor: 5.203

4.  The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.

Authors:  Moon-Taek Park; Min-Jeong Song; Eun-Taex Oh; Hyemi Lee; Bo-Hwa Choi; Seong-Yun Jeong; Eun-Kyung Choi; Heon Joo Park
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

5.  Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells.

Authors:  Ravi P Sahu; Ruifen Zhang; Sanjay Batra; Yan Shi; Sanjay K Srivastava
Journal:  Carcinogenesis       Date:  2009-06-23       Impact factor: 4.944

6.  Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis.

Authors:  Yan Shi; Ravi P Sahu; Sanjay K Srivastava
Journal:  BMC Cancer       Date:  2008-10-10       Impact factor: 4.430

7.  Inhalative exposure to vanadium pentoxide causes DNA damage in workers: results of a multiple end point study.

Authors:  Veronika A Ehrlich; Armen K Nersesyan; Kambis Atefie; Christine Hoelzl; Franziska Ferk; Julia Bichler; Eva Valic; Andreas Schaffer; Rolf Schulte-Hermann; Michael Fenech; Karl-Heinz Wagner; Siegfried Knasmüller
Journal:  Environ Health Perspect       Date:  2008-07-31       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.